Perry Scientific provides preclinical drug discovery and development services to pharmaceutical, biopharmaceutical and medical device sponsors. Our drug discovery team excels at conducting in vivo and in vitro studies in areas such as toxicity, pharmacokinetics, efficacy and stem cell biology research. A broad range of efficacy models for disease targets have been developed to assist in early lead selection or proof of concept studies. Models are available in various species including rodents, rabbits and swine. Other species can also be accommodated. We strive to provide quality and value while meeting rapid timeline requirements.

Toxicology/Pharmacokinetic Studies Include:

Acute, Sub-chronic, Chronic including Single Dose, Repeated Dose, Local Tolerance, and Carcinogenicity.

Efficacy evaluation Studies Include:

Dermatology:
Psoriasis, Wound healing, Inflammation, Eczema, Hair rowth, Skin grafting, Irritation and Sensitization

Oncology:
Xenograft and Syngenic models of cancer for colorectal, breast, prostate, pancreas, brain, head and neck, as well as other tumor types

Diabetes:
Streptozotocin (STZ) induced, Surgical pancreatectomy in varius species, Non-obese diabetic (NOD), db/db mice, Diet-Induced Obese (DIO), Zucker diabetic fatty rats (fa/fa)

Cardiovascular:
Myocardial Infarct, Atrial arrhythmias, Ventricular tachycardia, Ischemia, Coronary artery disease

Medical Device:
Surgical, Implantable, Biocompatibility, Drug delivery

Stem Cell:
Teratoma, Tumorigenicity, Efficacy, Distribution, Delivery